NAFLD fibrosis score is correlated with PCSK9 and improves outcome prediction of PCSK9 in patients with chest pain: a cohort study

Table 5 Cox regression analysis of PCSK9, NFS and the combination of NFS and PCSK9 with events in male and female

Variables		Male			Female
		Multivariable model			Multivariable model
	Events/ Subjects	OR(95%CI)	P	Events/ Subjects	OR(95%CI)	P
NFS per 1-SD increase	101/1215	1.528 (1.147,2.035)	0.004	57/793	1.033 (0.739,1.446)	0.848
PCSK9 per 1-SD increase	101/1215	1.344 (1.102,1.64)	0.004	57/793	1.042 (0.81,1.341)	0.747
PCSK9 + NFS
Low PCSK9 + low NFS	7/210	1.0		2/87	1.0
Low PCSK9 + intermediate-high NFS	20/265	1.907 (0.774,4.696)	0.161	8/107	2.32 (0.465,11.588)	0.310
Intermediate PCSK9 + low NFS	10/162	1.729 (0.65,4.603)	0.273	5/96	2.216 (0.419,11.721)	0.350
Intermediate PCSK9 + intermediate-high NFS	26/253	2.382 (0.985,5.764)	0.054	13/159	2.511 (0.524,12.024)	0.250
High PCSK9 + low NFS	11/134	2.236 (0.855,5.846)	0.101	10/109	3.361 (0.708,15.95)	0.130
High PCSK9 + intermediate-high NFS	27/191	3.377 (1.394,8.179)	0.007	19/235	2.178 (0.468,10.131)	0.320

PCSK9 proprotein convertase subtilisin/ kexin type 9, NFS non-alcoholic fatty liver disease fibrosis score, MACEs major adverse cardiovascular events, HR hazard ratio, CI confidence interval. Multivariable model was adjusted for body mass index, hypertension, family history of coronary artery disease, coronary artery disease, diabetes, smoking, drinking, triglyceride, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, fasting plasma glucose, hemoglobin A1c, antiplatelet drugs, antihypertensive drugs. P < 0.05 suggests significant difference

ISSN: 1476-511X